vs

Side-by-side financial comparison of CARTERS INC (CRI) and GENESIS ENERGY LP (GEL). Click either name above to swap in a different company.

CARTERS INC is the larger business by last-quarter revenue ($757.8M vs $440.8M, roughly 1.7× GENESIS ENERGY LP). GENESIS ENERGY LP runs the higher net margin — 4.5% vs 1.5%, a 3.0% gap on every dollar of revenue. On growth, GENESIS ENERGY LP posted the faster year-over-year revenue change (10.5% vs -0.1%). GENESIS ENERGY LP produced more free cash flow last quarter ($87.0M vs $-144.1M).

Carter's, Inc. is a major American designer and marketer of children's apparel. It was founded in 1865 by William Carter.

Genesis Energy LP is a U.S.-based midstream energy limited partnership that operates critical infrastructure for crude oil, natural gas, refined petroleum products, and specialty industrial materials. Its core assets include pipelines, storage terminals, marine facilities, and rail logistics hubs, serving refineries, industrial clients, and energy distributors across North America.

CRI vs GEL — Head-to-Head

Bigger by revenue
CRI
CRI
1.7× larger
CRI
$757.8M
$440.8M
GEL
Growing faster (revenue YoY)
GEL
GEL
+10.6% gap
GEL
10.5%
-0.1%
CRI
Higher net margin
GEL
GEL
3.0% more per $
GEL
4.5%
1.5%
CRI
More free cash flow
GEL
GEL
$231.1M more FCF
GEL
$87.0M
$-144.1M
CRI

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
CRI
CRI
GEL
GEL
Revenue
$757.8M
$440.8M
Net Profit
$11.6M
$19.9M
Gross Margin
45.1%
Operating Margin
3.8%
20.4%
Net Margin
1.5%
4.5%
Revenue YoY
-0.1%
10.5%
Net Profit YoY
-80.1%
140.2%
EPS (diluted)
$0.32
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRI
CRI
GEL
GEL
Q4 25
$440.8M
Q3 25
$757.8M
$414.0M
Q2 25
$585.3M
$377.3M
Q1 25
$629.8M
$398.3M
Q4 24
$398.9M
Q3 24
$397.3M
Q2 24
$430.2M
Q1 24
$434.4M
Net Profit
CRI
CRI
GEL
GEL
Q4 25
$19.9M
Q3 25
$11.6M
$9.2M
Q2 25
$446.0K
$-406.0K
Q1 25
$15.5M
$-469.1M
Q4 24
$-49.4M
Q3 24
$-17.2M
Q2 24
$-8.7M
Q1 24
$11.4M
Gross Margin
CRI
CRI
GEL
GEL
Q4 25
Q3 25
45.1%
Q2 25
48.1%
Q1 25
46.2%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
CRI
CRI
GEL
GEL
Q4 25
20.4%
Q3 25
3.8%
19.0%
Q2 25
0.7%
17.9%
Q1 25
4.1%
5.5%
Q4 24
3.4%
Q3 24
12.2%
Q2 24
11.6%
Q1 24
13.4%
Net Margin
CRI
CRI
GEL
GEL
Q4 25
4.5%
Q3 25
1.5%
2.2%
Q2 25
0.1%
-0.1%
Q1 25
2.5%
-117.8%
Q4 24
-12.4%
Q3 24
-4.3%
Q2 24
-2.0%
Q1 24
2.6%
EPS (diluted)
CRI
CRI
GEL
GEL
Q4 25
$0.04
Q3 25
$0.32
$-0.05
Q2 25
$0.01
$-0.12
Q1 25
$0.43
$-4.06
Q4 24
$-0.58
Q3 24
$-0.32
Q2 24
$-0.25
Q1 24
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRI
CRI
GEL
GEL
Cash + ST InvestmentsLiquidity on hand
$184.2M
$6.4M
Total DebtLower is stronger
$3.0B
Stockholders' EquityBook value
$864.6M
Total Assets
$2.5B
$4.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRI
CRI
GEL
GEL
Q4 25
$6.4M
Q3 25
$184.2M
$4.9M
Q2 25
$338.2M
$4.5M
Q1 25
$320.8M
$377.4M
Q4 24
$7.4M
Q3 24
$13.0M
Q2 24
$13.7M
Q1 24
$7.0M
Total Debt
CRI
CRI
GEL
GEL
Q4 25
$3.0B
Q3 25
$3.1B
Q2 25
$3.1B
Q1 25
$3.4B
Q4 24
$3.7B
Q3 24
$4.0B
Q2 24
$3.9B
Q1 24
$3.8B
Stockholders' Equity
CRI
CRI
GEL
GEL
Q4 25
Q3 25
$864.6M
Q2 25
$853.9M
Q1 25
$847.2M
Q4 24
Q3 24
Q2 24
Q1 24
Total Assets
CRI
CRI
GEL
GEL
Q4 25
$4.9B
Q3 25
$2.5B
$4.9B
Q2 25
$2.5B
$4.8B
Q1 25
$2.3B
$5.2B
Q4 24
$7.0B
Q3 24
$7.1B
Q2 24
$7.0B
Q1 24
$6.9B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRI
CRI
GEL
GEL
Operating Cash FlowLast quarter
$-128.0M
$110.8M
Free Cash FlowOCF − Capex
$-144.1M
$87.0M
FCF MarginFCF / Revenue
-19.0%
19.7%
Capex IntensityCapex / Revenue
2.1%
5.4%
Cash ConversionOCF / Net Profit
-11.04×
5.58×
TTM Free Cash FlowTrailing 4 quarters
$65.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRI
CRI
GEL
GEL
Q4 25
$110.8M
Q3 25
$-128.0M
$70.3M
Q2 25
$40.3M
$47.0M
Q1 25
$-48.6M
$24.8M
Q4 24
$74.0M
Q3 24
$87.3M
Q2 24
$104.7M
Q1 24
$125.9M
Free Cash Flow
CRI
CRI
GEL
GEL
Q4 25
$87.0M
Q3 25
$-144.1M
$43.3M
Q2 25
$24.1M
$-7.6M
Q1 25
$-59.0M
$-56.8M
Q4 24
$-47.1M
Q3 24
$-32.3M
Q2 24
$-67.5M
Q1 24
$-48.3M
FCF Margin
CRI
CRI
GEL
GEL
Q4 25
19.7%
Q3 25
-19.0%
10.5%
Q2 25
4.1%
-2.0%
Q1 25
-9.4%
-14.3%
Q4 24
-11.8%
Q3 24
-8.1%
Q2 24
-15.7%
Q1 24
-11.1%
Capex Intensity
CRI
CRI
GEL
GEL
Q4 25
5.4%
Q3 25
2.1%
6.5%
Q2 25
2.8%
14.5%
Q1 25
1.6%
20.5%
Q4 24
30.3%
Q3 24
30.1%
Q2 24
40.0%
Q1 24
40.1%
Cash Conversion
CRI
CRI
GEL
GEL
Q4 25
5.58×
Q3 25
-11.04×
7.63×
Q2 25
90.37×
Q1 25
-3.13×
Q4 24
Q3 24
Q2 24
Q1 24
11.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRI
CRI

Sales Channel Directly To Consumer$362.3M48%
Sales Channel Through Intermediary$283.8M37%
Other$110.4M15%
Gift Cards$1.3M0%

GEL
GEL

Onshore Facilities And Transportation Revenue$204.2M46%
Offshore Pipeline Transportation Revenue$154.3M35%
Marine Transportation Revenue$82.2M19%

Related Comparisons